bioAffinity Technologies, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $1.4M | $1.6M | $1.4M | $1.3M | $1.9M | $2.2M | $2.4M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $361.6K | $349.7K | $374.0K | $330.6K | $311.4K | $367.4K | $390.7K | $274.5K |
| SG&A Expense | $2.9M | $3.2M | $3.0M | $2.2M | $2.2M | $2.5M | $2.9M | $2.4M |
| Operating Income | $-3.3M | $-3.6M | $-3.1M | $-2.3M | $-2.5M | $-2.6M | $-2.9M | $-2.0M |
| Operating Margin | -220.8% | -267.6% | -196.9% | -158.6% | -198.2% | -141.7% | -133.5% | -84.0% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-3.4M | $-3.6M | $-3.1M | $-5.0M | $-4.0M | $-2.7M | $-3.0M | $-2.0M |
| Income Tax Expense | — | — | $3.2K | $3.2K | $29.0K | $8.7K | $0 | $2.6K |
| Net Income | $-3.4M | $-3.6M | $-3.1M | $-5.1M | $-4.1M | $-2.7M | $-3.0M | $-2.0M |
| Net Margin | -222.8% | -268.6% | -197.0% | -349.3% | -319.9% | -143.5% | -134.4% | -85.1% |
| EPS (Basic) | $-0.64 | $-0.81 | $5.95 | $-1.19 | $-1.27 | $-1.20 | $-4.32 | $-1.21 |
| EPS (Diluted) | $-0.64 | $-0.81 | $5.95 | $-1.19 | $-1.27 | $-1.20 | $-4.32 | $-1.21 |
| Shares Outstanding (Basic) | 5.2M | 4.5M | 1.7M | 4.3M | 3.2M | 2.2M | 1.6M | 1.7M |
| Shares Outstanding (Diluted) | 5.2M | 4.5M | 1.7M | 4.3M | 3.2M | 2.2M | 1.6M | 1.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |